FY2024 EPS Estimates for Dynavax Technologies Co. (NASDAQ:DVAX) Increased by Analyst

Dynavax Technologies Co. (NASDAQ:DVAX) – Analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Dynavax Technologies in a research note issued on Wednesday, August 7th. HC Wainwright analyst E. White now expects that the biopharmaceutical company will post earnings of $0.17 per share for the year, up from their prior forecast of $0.07. HC Wainwright has a “Buy” rating and a $29.00 price objective on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.12 per share. HC Wainwright also issued estimates for Dynavax Technologies’ Q4 2024 earnings at $0.02 EPS, FY2025 earnings at $0.20 EPS and FY2026 earnings at $0.33 EPS.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.02. Dynavax Technologies had a return on equity of 1.52% and a net margin of 3.91%. The firm had revenue of $73.80 million during the quarter, compared to the consensus estimate of $76.92 million. During the same period last year, the company earned $0.03 earnings per share.

Other equities research analysts also recently issued research reports about the company. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 28th. The Goldman Sachs Group decreased their price target on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a report on Thursday. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $23.67.

Dynavax Technologies Stock Performance

DVAX opened at $11.10 on Friday. The stock has a market cap of $1.45 billion, a P/E ratio of 185.00 and a beta of 1.28. The company has a debt-to-equity ratio of 0.36, a current ratio of 15.20 and a quick ratio of 14.10. Dynavax Technologies has a 1-year low of $9.74 and a 1-year high of $15.15. The stock’s 50 day simple moving average is $11.20 and its 200 day simple moving average is $11.84.

Insider Transactions at Dynavax Technologies

In related news, Director Francis Cano sold 3,615 shares of Dynavax Technologies stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $11.93, for a total transaction of $43,126.95. Following the transaction, the director now directly owns 36,905 shares of the company’s stock, valued at $440,276.65. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 2.98% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DVAX. Renaissance Technologies LLC raised its position in shares of Dynavax Technologies by 2.2% during the second quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock worth $27,830,000 after purchasing an additional 53,600 shares during the period. WINTON GROUP Ltd lifted its stake in Dynavax Technologies by 9.3% during the second quarter. WINTON GROUP Ltd now owns 82,403 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 7,025 shares in the last quarter. State of New Jersey Common Pension Fund D acquired a new position in shares of Dynavax Technologies in the second quarter worth about $1,811,000. Choreo LLC purchased a new position in shares of Dynavax Technologies in the second quarter worth approximately $363,000. Finally, Rhumbline Advisers raised its holdings in shares of Dynavax Technologies by 1.8% during the second quarter. Rhumbline Advisers now owns 310,805 shares of the biopharmaceutical company’s stock valued at $3,490,000 after acquiring an additional 5,379 shares during the period. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.